Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-6624 · 1 trial · 1 indication
To characterize the safety, tolerability, and pharmacokinetics (PK) of GS-6624 after multiple intravenous (IV) administrations in subjects with idiopathic pulmonary fibrosis (IPF).
| Arm | Type | Description |
|---|---|---|
| GS-6624 125mg | EXPERIMENTAL | - |
| Experimental: GS-6624 200mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GS-6624 | DRUG | Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period. |
Inclusion Criteria: 1. Acceptable results on pulmonary function tests 2. At rest oxygen saturation ≥90% on room air 3. Adequate organ function Exclusion Criteria: 1. High resolution computer tomography pattern showing emphysema that is greater than fibrosis 2. Acceptable results on whole body ple...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
GS-6624 is an investigational small molecule being studied for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. It is currently in Phase 1 clinical development and is not yet approved for any use.
GS-6624 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 1 clinical development for idiopathic pulmonary fibrosis.
GS-6624 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under investigation for idiopathic pulmonary fibrosis.
GS-6624 has one completed clinical trial, NCT01362231, which evaluated the safety and efficacy of the drug in patients with idiopathic pulmonary fibrosis. The trial enrolled 48 participants in the United States and was a controlled, randomized study.
Yes, GS-6624 was formerly known as AB0024. The clinical trial NCT01362231, which studied the drug in idiopathic pulmonary fibrosis, refers to GS-6624 as AB0024 in its title, indicating the name change.